Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer
Open Access
- 1 July 2002
- journal article
- clinical trial
- Published by BMJ in Journal of Clinical Pathology
- Vol. 55 (7) , 508-513
- https://doi.org/10.1136/jcp.55.7.508
Abstract
Aims: To compare the pathological stage and surgical margin status in patients undergoing either immediate radical prostatectomy or 12 and 24 weeks of neoadjuvant hormonal treatment (NHT) in a prospective, randomised study. Methods: Whole mount sections of 393 radical prostatectomy specimens were evaluated: 128 patients had immediate surgery, 143 were treated for 12 weeks and 122 for 24 weeks with complete androgen blockade. Results: Histopathology revealed organ confined tumours in 40.4% of patients with clinical stage B disease in the immediate surgery group, whereas 12 and 24 weeks of NHT increased the number of organ confined tumours to 54.6% and 64.8%, respectively. Among patients with clinical stage C tumours, pathological staging found organ confined disease in 10.4%, 31.4%, and 61.2% in the immediate surgery, 12 weeks of NHT, and 24 weeks of NHT groups, respectively. Preoperative NHT caused a significant decrease in positive margins both in patients with clinical stage B and C disease. The extent of margin involvement was not influenced by preoperative treatment. Conclusions: Neoadjuvant androgenic suppression is effective in reducing both the pathological stage and the positive margin rate in patients with stage B and C prostatic cancer undergoing radical surgery. Some beneficial effects are evident in those patients treated for 24 weeks, and it is reasonable to assume that the optimal duration of NHT is longer than three months.Keywords
This publication has 18 references indexed in Scilit:
- RANDOMIZED COMPARATIVE STUDY OF 3 VERSUS 8-MONTH NEOADJUVANT HORMONAL THERAPY BEFORE RADICAL PROSTATECTOMY: BIOCHEMICAL AND PATHOLOGICAL EFFECTSJournal of Urology, 2001
- 4–Year Follow–Up Results of a European Prospective Randomized Study on Neoadjuvant Hormonal Therapy prior to Radical Prostatectomy in T2–3N0M0 Prostate CancerEuropean Urology, 2000
- Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.2000
- Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapyUrology, 1999
- Neoadjuvant hormonal therapy: The Canadian experienceUrology, 1997
- Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2–3 N0 M0 prostatic carcinomaUrology, 1997
- The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center resultsUrology, 1997
- WHY NEOADJUVANT ANDROGEN DEPRIVATION PRIOR TO RADICAL PROSTATECTOMY IS UNNECESSARYUrologic Clinics of North America, 1996
- Neoadjuvant Hormonal Therapy Before Radical Prostatectomy Decreases the Number of Positive Surgical Margins in Stage T2 Prostate CancerJournal of Urology, 1995
- Therapy of prostatic cancer and histopathologic follow‐upThe Prostate, 1982